Real-world effectiveness and safety of first-line chemoimmunotherapy combinations in metastatic non-small cell lung cancer with programmed death ligand-1 < 50%: results from an Italian observational study

Real-world effectiveness and safety of first-line chemoimmunotherapy combinations in metastatic non-small cell lung cancer with programmed death ligand-1 < 50%: results from an Italian observational study

Abstract Introduction This multi-center, observational cohort study aimed to evaluate the real-world effectiveness and safety of two first-line chemoimmunotherapy combinations—pembrolizumab plus chemotherapy and nivolumab/ipilimumab plus chemotherapy—in patients with metastatic non-small cell lung c...

Full description

Saved in:
Bibliographic Details
Main Authors: Alessandro Inno, Antonello Veccia, Ettore D’Argento, Floriana Morgillo, Elio Gregory Pizzutilo, Fabiana Vitiello, Alberto Pavan, Fiorella Lombardo, Marco Russano, Vincenzo Sforza, Francesca Colamartini, Carlo Genova, Rita Chiari, Antonella Cristofano, Alessandro Delconte, Emanuela Vattemi, Alessandra Dessi, Daniele Galanti, Simona Busato, Giovanni Palazzolo, Clementina Savastano, Antonio Bianco, Francesco Verderame, Cristina Mazzi, Fabiana Marchetti, Stefania Kinspergher, Denis Occhipinti, Carminia Maria Della Corte, Daniele Piscazzi, Marina Gilli, Emilio Bria, Orazio Caffo, Stefania Gori
Format: Article
Language:English
Published: Springer 2025-07-01
Series:Cancer Immunology, Immunotherapy
Subjects:
Pembrolizumab
Nivolumab
Ipilimumab
Chemotherapy
NSCLC
PD-L1
Online Access:https://doi.org/10.1007/s00262-025-04125-w
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s00262-025-04125-w

Similar Items